Arrowhead Pharmaceuticals, Inc. Share Price & Technical Analysis
ARWR · $74.95 (-0.78%)
Healthcare / Biotechnology
$74.95
-0.78%
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
0% return in May, 5% avg return in past 3 year May month.
15% return in 2026, 40% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 5% | -8% | 2% | 16% | 0% | – | – | – | – | – | – | – | 15% |
| 25 | 5% | -1% | -33% | 9% | 16% | -2% | 1% | 42% | 52% | 23% | 25% | 27% | 164% |
| 24 | 5% | 0% | -12% | -20% | 1% | 10% | 11% | -16% | -19% | 0% | 33% | -27% | -34% |
| 23 | -14% | -7% | -22% | 39% | -2% | 3% | -3% | -20% | -3% | -7% | -17% | 42% | -10% |
| 22 | -20% | -17% | 5% | -11% | -19% | 4% | 20% | -5% | -16% | 5% | -10% | 26% | -38% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$10.96B
P/E ratio
—
52W high
$82.26
52W low
$14.30
Volume
14,01,643
Beta
1.29
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Arrowhead Pharmaceuticals, Inc. share price today?
- Arrowhead Pharmaceuticals, Inc. (ARWR) last traded around $74.95 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ARWR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ARWR. Download the app for real-time alerts.
- How can I analyze Arrowhead Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.